Tofacitinib et risque de tumeur maligne : Résultats de l'étude sur l'innocuité du tofacitinib chez les patients atteints de polyarthrite rhumatoïde et recevant des soins de routine (STAR-RA)
Arthritis Rheumatol. 2022;74:1648–1659 doi: 10.1002/art.42250
Large, population-based, real-world cohort of study in patients with RA finds tofacitinib not to be associated with an increased risk of malignancies, in comparison to TNFi agents, although a numerically increased risk of malignancies was observed in older patients with risk factors for cardiovascular disease.